观察门冬胰岛素和生物合成人胰岛素对妊娠期糖尿病(GDM)血糖控制与并发症的影响

目的:探讨门冬胰岛素和生物合成人胰岛素对妊娠期糖尿病(GDM)血糖控制与并发症的影响。方法:通过对2018年2月~2019年12月在某院治疗126例妊娠期糖尿病患者分组,分为对照组和实验组,对照组采用生物合成人胰岛素治疗,实验组采用门冬胰岛素和生物合成人胰岛素治疗,观察比较两组血糖水平、血清氧化物水平、母婴结局、不良反应发生率差异。结果:治疗后实验组HbAlc(5.24±0.67)%、FBG(5.21±0.77)mmol/L、2hPG(5.42±0.63)mmol/L均明显低于对照组(P<0.05);两组治疗后丙二醛(MDA)、活性氧(ROS)、超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-PX)较治疗前均显著改善(P<0.05),治疗后实验组MDA(60.24±5.02)mmol/ml明显高于对照组(P<0.05);实验组产后出血(3.17%)、低体重儿(4.76%)、胎儿窘迫(1.59%)、新生儿窒息(0.00%)均显著低于对照组(P<0.05);实验组不良反应发生率(9.52%)和对照组比较差异无统计学意义。结论:针对妊娠期糖尿病患者应用门冬胰岛素联合生物合成人胰岛素治疗可有效控制血糖,调节血清氧化物和抗氧化物平衡,改善母婴结局,安全性高,值得推广应用。

The Effects of Insulin Aspart and Biosynthetic Human Insulin on Blood Glucose Control and Complications of Gestational Diabetes Mellitus (GDM)

Objective:To investigate the effects of insulin aspart and biosynthetic human insulin on blood glucose control and complications of gestational diabetes mellitus(GDM).Methods:126 cases of gestational diabetes patients treated in a hospital from February 2018 to December 2019 were divided into two groups.The control group was treated with biosynthetic human insulin,and the experimental group was treated with insulin aspart and biosynthetic human insulin.The difference in blood glucose levels,serum oxide levels,maternal and infant outcomes,and incidence of adverse reactions between the groups were observed and compared.Results:After treatment,HbAlc(5.24±0.67)%,FBG(5.21±0.77)mmol/L and 2hPG(5.42±0.63)mmol/L of the experimental group were significantly lower than those of the control group(P<0.05);Dialdehyde(MDA),reactive oxygen species(ROS),superoxide dismutase(SOD),and glutathione peroxidase(GSH-PX)after treatment were significantly improved compared with before treatment(P<0.05),and the MDA(60.24±5.02)mmol/ml in the experimental group after treatment was significantly higher than that of the control group(P<0.05);The postpartum hemorrhage(3.17%),low birth weight infants(4.76%),fetal distress(1.59%),and neonatal asphyxia(0.00%)in the experimental group were significantly lower than those in the control group(P<0.05);The incidence of adverse reactions in the experimental group was 9.52%,and there was no significant difference between the two groups.Conclusion:The treatment of insulin aspart combined with biosynthetic human insulin for patients with gestational diabetes can effectively control blood glucose,regulate the balance of serum oxides and antioxidants,and improve maternal and infant outcomes,with high safety,which is worthy of promotion and application.